161 related articles for article (PubMed ID: 24684173)
1. Gliptins - do they increase cardiovascular risk or benefit?
Doggrell SA; Dimmitt SB
Expert Opin Drug Saf; 2014 May; 13(5):675-80. PubMed ID: 24684173
[TBL] [Abstract][Full Text] [Related]
2. Saxagliptin, alogliptin, and cardiovascular outcomes.
Standl E
N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
[No Abstract] [Full Text] [Related]
3. [New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)].
Gallwitz B; Nitschmann S
Internist (Berl); 2014 Jul; 55(7):859-62. PubMed ID: 24969610
[No Abstract] [Full Text] [Related]
4. Diabetes: Cardiovascular safety of 'gliptin' therapy.
Lim GB
Nat Rev Cardiol; 2013 Nov; 10(11):616. PubMed ID: 24042219
[No Abstract] [Full Text] [Related]
5. Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Greenhill C
Nat Rev Endocrinol; 2013 Nov; 9(11):625. PubMed ID: 24061081
[No Abstract] [Full Text] [Related]
6. Saxagliptin, alogliptin, and cardiovascular outcomes.
White WB; Zannad F
N Engl J Med; 2014 Jan; 370(5):484. PubMed ID: 24482824
[No Abstract] [Full Text] [Related]
7. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Clifton P
Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
[TBL] [Abstract][Full Text] [Related]
8. An update on the 'gliptins'.
Drug Ther Bull; 2016 Dec; 54(12):138-141. PubMed ID: 27979881
[TBL] [Abstract][Full Text] [Related]
9. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
[TBL] [Abstract][Full Text] [Related]
10. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Špinar J; Špinarová L; Vítovec J
Vnitr Lek; 2015 Nov; 61(11):976-83. PubMed ID: 26652787
[TBL] [Abstract][Full Text] [Related]
11. Saxagliptin, alogliptin, and cardiovascular outcomes.
Scirica BM; Braunwald E; Bhatt DL
N Engl J Med; 2014 Jan; 370(5):483-4. PubMed ID: 24476444
[No Abstract] [Full Text] [Related]
12. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Cushman WC; Zannad F;
N Engl J Med; 2013 Oct; 369(14):1327-35. PubMed ID: 23992602
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
White WB; Wilson CA; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Heller SK; Mehta CR; Nissen SE; Zannad F; Kupfer S;
Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
[TBL] [Abstract][Full Text] [Related]
15. Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
Prescrire Int; 2011 Feb; 20(113):33-7. PubMed ID: 21488586
[TBL] [Abstract][Full Text] [Related]
16. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Schernthaner G; Cahn A; Raz I
Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
[No Abstract] [Full Text] [Related]
17. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.
Hirshberg B; Katz A
Curr Diab Rep; 2015 Nov; 15(11):87. PubMed ID: 26370698
[TBL] [Abstract][Full Text] [Related]
18. New oral hypoglycaemics fail to show cardiovascular benefits.
Cohen D
BMJ; 2013 Sep; 347():f5458. PubMed ID: 24014343
[No Abstract] [Full Text] [Related]
19. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
20. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]